(4R)-N-(2-Nitrooxypropyl)-2-oxothiazolidine-4-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-N-(2-Nitrooxypropyl)-2-oxothiazolidine-4-carboxamide
• 英文别名: 1-[[(4R)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]propan-2-yl nitrate
• 化学式: C₇H₁₁N₃O₅S
• 分子量: 249.247
• InChiKey: WQBYSLFCSRVEAH-AKGZTFGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  nitric acid-(β-amino-isopropyl ester); nitrate 、 丙半胱氨酸 在 title compound 、 乙醇 作用下， 生成 (4R)-N-(2-Nitrooxypropyl)-2-oxothiazolidine-4-carboxamide
  参考文献：
  名称：

  Oxazolidinone compounds and method of using the same as a vasodilator

  摘要：

  公式（I）的化合物：##STR1## 其中W代表氧原子，X代表公式--N（R.sup.1）-的基团; R.sup.1是氢，烷基或芳基烷基; R.sub.2和R.sup.3分别是氢，烷基，芳基烷基，芳基或芳香族杂环; R.sup.4是氢，烷基或芳基烷基; A是可选地取代羧基的烷基;以及其药学上可接受的盐和酯，具有有价值的血管扩张活性。

  公开号：

  US05356918A1

文献信息

• Oxazolidinone compounds and method of using the same as a vasodilator
  申请人：Sankyo Company, Ltd.

  公开号：US05356918A1

  公开（公告）日：1994-10-18

  Compounds of formula (I): ##STR1## wherein W represents an oxygen atom and X represents a group of formula --N(R.sup.1)--; R.sup.1 is hydrogen, alkyl or aralkyl; R.sub.2 and R.sup.3 are each hydrogen, alkyl, aralkyl, aryl or aromatic heterocyclic; R.sup.4 is hydrogen, alkyl or aralkyl; and A is alkylene which is optionally substituted by carboxy; and pharmaceutically acceptable salts and esters thereof, have a valuable vasodilatory activity.

  公式（I）的化合物：##STR1## 其中W代表氧原子，X代表公式--N（R.sup.1）-的基团; R.sup.1是氢，烷基或芳基烷基; R.sub.2和R.sup.3分别是氢，烷基，芳基烷基，芳基或芳香族杂环; R.sup.4是氢，烷基或芳基烷基; A是可选地取代羧基的烷基;以及其药学上可接受的盐和酯，具有有价值的血管扩张活性。
• Thiazolidinone and oxazolidinone derivatives, their preparation and their use as vasodilators
  申请人：Sankyo Company Limited

  公开号：EP0506434A1

  公开（公告）日：1992-09-30

  Compounds of formula (I): in which: W represents a sulphur or oxygen atom and X represents a group of formula -N(R¹)-, or W represents a group of formula -N(R¹)- and X represents a sulphur or oxygen atom; R¹ is hydrogen, alkyl or aralkyl; R² and R³ are each hydrogen, alkyl, aralkyl, aryl or aromatic heterocyclic; R⁴ is hydrogen, alkyl or aralkyl; and A is alkylene which is optionally substituted by carboxy; and pharmaceutically acceptable salts and esters thereof, have a valuable vasodilatory activity.

  式(I)化合物： 其中W代表硫原子或氧原子，X代表式-N(R¹)-的基团，或W代表式-N(R¹)-的基团，X代表硫原子或氧原子；R¹为氢、烷基或芳烷基；R²和R³分别为氢、烷基、芳烷基、芳基或芳香杂环基；R⁴为氢、烷基或芳烷基；A为任选被羧基取代的亚烷基；以及它们的药学上可接受的盐和酯，具有宝贵的血管扩张活性。
• Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties
  作者：Sadao Ishihara、Fujio Saito、Yasuo Ohhata、Marie Kanai、Hiroshi Mizuno、Michio Fujisawa、Ryosuke Yorikane、Hiroyuki Koike

  DOI：10.1016/s0960-894x(03)00199-9

  日期：2003.5

  To develop an orally active, long-acting nitrate that does not induce tolerance, nitroxyalkyl compounds were prepared and their activities evaluated by the use of carotid collaterals in anesthetized dogs. A compound having a favorable pharmacological profile, that is, long-lasting collateral vasodilatation and little hypotension, and lack of nitrate tolerance, was chosen for further evaluation. (C) 2003 Elsevier Science Ltd. All rights reserved.
• US5298516A
  申请人：——

  公开号：US5298516A

  公开（公告）日：1994-03-29
• US5356918A
  申请人：——

  公开号：US5356918A

  公开（公告）日：1994-10-18